Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study

Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US

The FDA lifted a hold on Arbutus' experimental oral hepatitis B drug.

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

ABUS Looks 89.5% Undervalued on GF Value™ Amid Share Buyback Ann

Arbutus Biopharma shares jump after unveiling $230 million share buyback plan

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?

Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?